REG - Tate & Lyle PLC - Board Changes

Tate & LyleAnnouncement

30/12/2020 13:00

RNS Number : 1356K
  
Tate & Lyle PLC
  
30 December 2020
  
 

30 December 2020
 
Tate & Lyle PLC
 
 
BOARD CHANGES
 
Tate & Lyle PLC (the "Company") announces that John Cheung will join the Board as a non-executive director and a member of the Audit and Nominations Committees on 1 January 2021.  
 
Currently an executive director of nutrition group China Feihe Limited, John brings a breadth of food and beverage experience with a deep understanding of markets in Asia, particularly in China.  In a career spanning 30 years in the fields of nutrition, food and beverages, John has served as President for Wyeth Nutrition Global, having previously served as Nestlé Group's leader in China and earlier held senior roles with Coca-Cola and Procter & Gamble.
 
After nearly nine years on the Board, the Company also announces that non-executive director, Dr Ajai Puri, will retire on 31st March 2021.
 
Dr Gerry Murphy, Chairman of Tate & Lyle, said: "I am delighted that John has agreed to join the Board. His appointment recognises the importance of the Asia Pacific region to Tate & Lyle's growth and development. His substantial experience in the Chinese and broader Asian food and beverage industry will be of significant benefit to the Board.
 
I also thank Dr Puri for his nine years of dedicated service and significant contribution to the Board and, in particular, for his time as Chairman of our Research Advisory Group.  Ajai's wisdom, technological insights and management experience have been exceptionally valuable as Tate & Lyle has evolved into a global, science-led food ingredient business."
 
There are no further disclosures to be made in connection with Mr Cheung's appointment pursuant to paragraph 9.6.13 of the Financial Conduct Authority's Listing Rules.
 
END
 
For more information contact



Nick Hasell, FTI Consulting (Media)

Tel: Mobile: +44 (0) 7825 523 383


Christopher Marsh, VP, Investor Relations

chris.marsh@tateandlyle.com / +44 (0) 7796 192 688
 
About Tate & Lyle: 



Tate & Lyle PLC is a leading global provider of food and beverage ingredients and solutions.  Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.
Through our expertise in sweetening, mouthfeel and fibre fortification, our Food & Beverage Solutions business develops solutions which reduce sugar, calories and fat, add fibre, and provide texture and stability in categories including beverages, dairy, bakery, soups, sauces and dressings.  Our Primary Products business produces nutritive sweeteners, industrial starches used in paper and packaging, acidulants and products used for animal nutrition.
We have around 4,200 employees working in more than 60 locations across 30 countries. Tate & Lyle's purpose is Improving Lives for Generations and through our purpose we believe we can successfully grow our business and have a positive impact on society.  We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet. 
Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2020, Tate & Lyle sales totalled £2.9 billion.  For more information, please visit http://www.tateandlyle.com or follow Tate & Lyle on Twitter or Linkedin.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
BOAWPGQCPUPUUBU